HESHAMMOHAMEDHESHAM MOHAMED15268MOHAMED, HESHAMprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonLeukemiaMD AndersonJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorSRDANVERSTOVSEKSRDAN VERSTOVSEK8781VERSTOVSEK, SRDANProfessorELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate ProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessor24569263Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Br?mmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio GBloodLong-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24.Blood2014-02-25T00:00:002014Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.24311723Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu? C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus ABloodEarly response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500.Blood2013-12-05T00:00:002013Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).74Professor14Associate ProfessorD047428Chemicals & Drugs87447520.324883Protein Kinase Inhibitors26998677Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NPCancerLymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407.Cancer2016-03-21T00:00:002016Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.27192969Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio GAmerican journal of hematologyDasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74.Am J Hematol2016-06-20T00:00:002016Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.D015466Disorders515050.69359Leukemia, Myeloid, Chronic-PhaseD00006887727516650.710174Imatinib MesylateD0000694392238640.743537DasatinibD000071036712150.805867Sentinel Lymph Node3701 KIRBY DRIVEHouston, 77098TX0.4901590.011024673research areas0.3611240.09812153coauthor of41.26731.6960460similar to1110selected publicationsAuthorship 97063012Authorship 9714178Authorship 9716548Authorship 9723196Authorship 9725387Authorship 973586329556695Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, Pinilla-Ibarz J, Abruzzese EAnnals of hematologyOutcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018 Aug; 97(8):1357-1367.Ann Hematol2018-03-20T00:00:002018Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.27133948Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot FClinical lymphoma, myeloma & leukemiaCross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):341-349.e1.Clin Lymphoma Myeloma Leuk2016-03-29T00:00:002016Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.Authorship 105702827Authorship 1058575429930251Kylm? AK, Jouhi L, Listyarifah D, Mohamed H, M?kitie A, Remes SM, Haglund C, Atula T, Nieminen MT, Sorsa T, Hagstr?m JBritish journal of cancerTreponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma. Br J Cancer. 2018 07; 119(1):89-95.Br J Cancer2018-06-22T00:00:002018Treponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma.36370742Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, R?cher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JEThe Lancet. HaematologyOlutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2022 Nov 09.Lancet Haematol2022-11-09T00:00:002022Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Authorship 1072088628464452Jouhi L, Atula T, Saarilahti K, Hagstr?m J, Haglund C, Mohamed H, M?kitie A, Keski-S?ntti HHead & neckChanging trends in the management of the neck in oropharyngeal squamous cell carcinoma. Head Neck. 2017 07; 39(7):1412-1420.Head Neck2017-05-02T00:00:002017Changing trends in the management of the neck in oropharyngeal squamous cell carcinoma.Authorship 1086315337061649Fadel MG, Rauf S, Mohamed HS, Yusuf S, Hayes AJ, Power K, Smith MJAnnals of surgical oncologyThe Use of Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye in Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Retrospective, Cohort Study. Ann Surg Oncol. 2023 Jul; 30(7):4333-4340.Ann Surg Oncol2023-04-16T00:00:002023The Use of Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye in Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Retrospective, Cohort Study.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor